Back to Results
First PageMeta Content
Financial ratios / Business / Accountancy / Earnings before interest / taxes / depreciation and amortization / Private equity / EV/EBITDA / Glenmark Pharmaceuticals / Glenmark / Financial analyst / Finance / Fundamental analysis / Valuation


GNP[removed]MOSL-RU-8PG.p65
Add to Reading List

Document Date: 2012-11-12 02:07:06

Open Document

File Size: 218,84 KB

Share Result on Facebook

Company

Glenmark Pharmaceuticals / Adjusted PAT / Glenmark Pharmaceuticals No No No No / Marco Polo Securities Inc. / S&P / Bloomberg / Cipla / Glenmark Pharmaceuticals Glenmark Pharmaceuticals / Glenmark Pharmaceuticals Net Working Capital / Motilal Oswal Securities Limited / /

Country

Japan / United States / United Kingdom / India / /

Currency

USD / Rs / /

/

Event

Conference Call / Accounting Change / /

Facility

Motilal Oswal Securities Ltd Motilal Oswal Tower / /

IndustryTerm

pharmaceutical / /

Organization

FDA / U.S. Securities and Exchange Commission / NASD / FINRA / /

Person

Nimish Desai / /

/

Position

independent financial advisor / research analyst / growth driver / Analyst / Major Institutional Investors / registered broker-dealer in the United States / /

Technology

drug discovery / CMP / /

SocialTag